Compare SMTI & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMTI | NMRA |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.5M | 302.0M |
| IPO Year | 2008 | 2023 |
| Metric | SMTI | NMRA |
|---|---|---|
| Price | $35.08 | $0.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $34.00 | $7.50 |
| AVG Volume (30 Days) | 191.0K | ★ 1.5M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,586,976.00 | N/A |
| Revenue This Year | $17.31 | N/A |
| Revenue Next Year | $12.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $0.63 |
| 52 Week High | $35.34 | $3.65 |
| Indicator | SMTI | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 67.59 | 22.81 |
| Support Level | $33.99 | N/A |
| Resistance Level | $35.34 | $1.74 |
| Average True Range (ATR) | 0.21 | 0.10 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 55.56 | 6.63 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.